Joaquim Bellmunt: The role of mTORC1/2 inhibitor sapanisertib

Petros Grivas shared an article by Joaquim Bellmunt on X:

“Congrats Joaquim Bellmunt and your team Dana-Farber Lank Center for Genitourinary Oncology.”

Quoting Joaquim Bellmunt‘s post:

“Interesting data to confirm in a clinical trial.
Our article “Enhancing IO-therapy through PD-L1 upregulation: the promising combination of anti-PD-L1 + mTOR inhibitors” online in Molecular Oncology
Expanding the role of mTORC1/2 inhibitor sapanisertib (TAK-228)”

Title: Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors

Authors: Anna Hernández-Prat, Alejo Rodriguez-Vida, Laura Cardona, Mengjuan Qin, Oriol Arpí-Llucià, Luis Soria-Jiménez, Sílvia Menendez, Fabricio Gerel Quimis, Miguel Galindo, Edurne Arriola, Marta Salido, Nuria Juanpere-Rodero, Federico Rojo, Aura Muntasell, Joan Albanell, Ana Rovira and Joaquim Bellmunt

Source: Petros Grivas/X and Joaquim Bellmunt/X

 Dr. Petros Grivas, a board-certified medical oncologist, serves as Clinical Director of the Genitourinary Cancers Program at the University of Washington and Seattle Cancer Care Alliance. He’s an Associate Professor at the Dept. of Medicine and Associate Member at Fred Hutchinson Cancer Research Center since January 2018. With extensive training and experience, he’s led clinical trials, contributing to FDA approvals for bladder/urothelial cancer treatments.